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a b s t r a c t
A method was developed for the quantiﬁcation of araCTP, CTP and dCTP in a human follicular lymphoma
cell line. This method involves solid phase extraction (SPE) using a weak anion-exchanger (WAX) car-
tridge, a porous graphitic carbon high-performance liquid chromatography (HPLC) column separation,vailable online 17 March 2009
eywords:
raCTP
TP
C/MS/MS
and tandemmass spectrometry (MS/MS) detection. By using a triple quadrupolemass spectrometer oper-
ating in negative ion multiple reaction monitoring (MRM) mode, the method was able to achieve a lower
limit of quantiﬁcation (LLOQ) of 0.1gmL−1 for araCTP and of 0.01gmL−1 for both CTP and dCTP. The
methodwas validated andused to determine the amount of araCTP, CTP anddCTP formed after incubation
of araC and an araCMP prodrug in the human follicular lymphoma cell line RL.AX
orous graphitic carbon
. Introduction
Nucleoside analogs represent a group of cytotoxic antimetabo-
ites used for the treatment of haematological malignancies and
olid tumors [1]. AraC (1--d-arabinofuranosylcytosine, cytara-
ine) a deoxycytidine analog, is one of the most important
ntileukemic drug currently available for the treatment of acute
yeloid leukaemia [2,3]. The cellular metabolism of araC is similar
o that of its physiological deoxyribonucleoside counterpart (dC).
nce inside the cell, araC is successively phosphorylated by cellular
inases to its 5′-monophosphate (araCMP) (Fig. 1), 5′-diphosphate
araCDP), and then cytotoxic 5′-triphosphate derivative (araCTP)
hich interferes with the biosynthesis of DNA [4–6]. The enzyme
eoxycytidine kinase (dCK), is known to catalyze theﬁrst step of the
equential phosphorylation of araC to araCTP. As the therapeutic
fﬁciency of araC strongly depends on its intracellular conversion
o the corresponding 5′-triphosphate form, there is a correlation
∗ Corresponding author. Tel.: +33 467143210; fax: +33 467042029.
E-mail addresses: isabelle.tournier@univ-montp2.fr, tournier@univ-montp2.fr 
I. Lefebvre).between the cellular accumulation of araCTP and the cytotoxic-
ity effect of araC in vitro and in clinical samples [3]. Moreover, in
vitro and in vivo prolonged treatment with araC has resulted in
the emergence of drug resistant cells with diminished sensitivity
to the drug, thus contributing to treatment failures [3,7,8]. Several
mechanismsof resistance to araChavebeen reported [9] andamong
them, dCKdeﬁciencyhas been associatedwith reduced araCTP con-
centrations in various cells and animal models [10]. Consequently,
the intracellular quantiﬁcation of araCTP is critical in the clinical
pharmacokinetic data for determination of an appropriate dosing
regimen and to detect resistance mechanisms.
However, biological activity of araC depends not only on the
intracellular concentrations of araCTP but also on the endoge-
nous nucleotide pools (CTP and dCTP) since araCTP will compete
with dCTP for incorporation into DNA, and to a lesser extent with
CTP for incorporation into RNA. In this respect, the concentration
ratios of araCTP versus dCTP (araCTP/dCTP) and of araCTP ver-
sus CTP (araCTP/CTP) could be considered as a predictive marker
of therapeutic efﬁcacy [11]. Consequently, direct access to such
ratios in individual patient samples could prove to be helpful in
understanding and/or predicting which patients will respond to
araC-containing regimens.
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oFig. 1. Chemical structures of araCTP, CTP, dCTP, BrATP (int
The measurement of intracellular concentration of therapeutic
ucleosides triphosphates (NuTPs) by LC/MS/MS is especially chal-
enging because of the presence of very high levels of endogenous
ompounds. Mass spectrometry provides a detection method with
ensitivity and speciﬁcity suitable for intracellular measurements
ut it is not typically compatible with LC methods for resolv-
ng nucleotides. Furthermore, nucleotides are difﬁcult to analyse
y traditional LC/MS/MS methodologies because of their polar
ature that hampers their retention by reversed phase (RP) chro-
atography using typical aqueous-organic mobile phases. Some
hromatographic separations have been successfully developed
nd validated using anion exchange chromatography or reversed
hase with ion-pairing agents. As an example, the use of weak
nion exchange (WAX) column coupled to MS/MS detection has
een described in the literature [12]. However, high salt concen-
rations and non-volatile ion-pairing agents preclude the use of
ass spectrometry (MS) for detection. Therefore, the type of ion-
air agent and its subsequent concentration should be optimized.
hus, the ion-pair agent would act as a counter ion for the acidic
ucleotides, thereby facilitating their elution from the column.
or instance, dimethylhexyl amine (DEA) [13–19] or tetrabutylam-
onium (TBA) [20,21] have been reported in the literature. As
ndogenous CTP and araCTP exhibit the same molecular mass and
he same MS/MS transitions, a chromatographic baseline separa-
ion between these compoundswas required prior toMS detection.
everal assays for the detection and determination of araCTP have
een published using tritium-labelled araC [22]. Separation of
etabolites was performed using ionic chromatography with UV
etection [23] or scintillation spectrometry [24], but never by
C/MS/MS. This paper describes the development and validation
f an ion-pair LC/MS/MS method for the simultaneous analysisstandard) ClATP (internal standard) and bis(SATE) araCMP.
of araCTP, CTP and dCTP in human follicular lymphoma cell line
(RL) and in a dCK-deﬁcient human follicular lymphoma cell line
(RL-G) using a porous graphitic carbon (PGC) stationary phase cou-
pled with electrospray ionization (ESI) mass spectrometry. One
application of this method is illustrated by an experiment in cell
lines.
2. Materials and methods
2.1. Chemicals
2-Chloroadenosine 5′-triphosphate (ClATP) and araCTP were
synthesized following a published procedure [25]. 13C9,15N3-
Cytidine 5′-triphosphate (CTP*), 13C9,15N3-2′-deoxycytidine 5′-
triphosphate (dCTP*), 2′-deoxycytidine 5′-triphosphate (dCTP),
cytidine 5′-triphosphate (CTP), 8-bromoadenosine 5′-triphosphate
(BrATP) used as internal standard (IS) for NuTP were obtained from
Sigma–Aldrich (Saint Quentin, France). The bis(SATE) prodrug of
araCMP(compound1, Fig. 1)was synthesized followingapreviously
published procedure [26].
High-performance liquid chromatography (HPLC) grade ace-
tonitrile and methanol were purchased from Carlo Erba (Val-
de-Reuil, France). Other chemicals, 99.5% (v/v) diethylamine and
99% (v/v) ammonium acetate and glacial acetic acid from Fluka,
99% (v/v) hexylamine from Acros Organics, 28% (v/v), rectapur
concentrated NH4OH from Fisher Scientiﬁc. Ultrapure water was
from a Milli-Q puriﬁer (Millipore, France). Nitrogen was from Air
Liquide (Paris, France). GV springe ﬁlters (0.45m) were from Mil-
lipore (Yonezawa, Japan). Phosphate buffered saline (PBS)was from
Biowhittaker (Emerainville, France). RPMI 1640 (order number
21875) medium-containing l-glutamine, penicillin–streptomycin
Table 1
Method gradient proﬁle, ﬂow-rate 0.3mLmin−1.
Time (min) Percentage of mobile phase in the eluent
A B
0 100 0
15 70 30
25 70 30
35 0 100
36 100 0
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A) HA (5mM) with DEA (0.4%, v/v), the pH was adjusted to 10 with glacial acetic
cid. (B) Acetonitrile and water (1/1, v/v).
nd fetal bovine serum heat-inactivated were obtained from Gibco
Cergy Pontoise, France).
.2. Instrumentation
LC instrumentation included an ACQUITYTM Ultra Performance
iquid Chromatography integrated system from Waters (Milford,
A, USA), set at 272nm. MS experiments were performed using
triple quadrupole mass spectrometer TSQ Quantum UltraTM
Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA).
LC conditions. Separation was performed on a hypercarb col-
mn, 5m, 50mm×2.1mm (ThermoFisher). The mobile phase
onsisted of two eluents. Eluent A was hexylamine (HA, 5mM)
ith DEA (0.4%, v/v), the pH was adjusted to 10 with glacial acetic
cid. Eluent B was acetonitrile/water (50/50, v/v). The ﬂow-rate
as 0.3mLmin−1 and the temperature of the analytical column
as maintained at 30 ◦C. The autosampler temperature was kept at
◦C. The method gradient proﬁle was presented in Table 1. 10L of
ample was injected with full loop mode.
Mass spectrometric conditions. Ionization was performed using
n electrospray ionization source operating in the negative ion
ode. The sheath and auxiliary gas were set at 45 and 35arbitrary
nits (au), respectively (all N2). The collision gas (argon) pressure
as set at 1.7mTorr. The spray voltage was 3000V. The capillary
as heated to 380 ◦C. A 0.7 full width half mass (FWHM) resolu-
ion (unit resolution) of the hyperquadswas used for all transitions.
he source collision-induced dissociation (CID) was not used. The
nstrument was optimized for araCTP, CTP*, dCTP*, CTP, dCTP, ClATP
nd BrATP by infusing a 2.5gmL−1 solution of each compound in
cetonitrile/water (50/50, v/v) at 10Lmin−1. Data was acquired
singXcalibur 2.0 software (ThermoFisher Scientiﬁc Inc.). Themul-
iple reaction monitoring (MRM) transitions of m/z 585–159, m/z
25–159, m/z 482–159, m/z 494–159, m/z 482–159, m/z 478–159
nd m/z 466–159 were chosen for BrATP, ClATP, araCTP, CTP*, CTP,
CTP* and dCTP, respectively.
.3. Cell culture
The RL-7 cells are derived from a human follicular lymphoma
27]. The resistant variantRL-Gwhich is dCK-deﬁcientwasobtained
y exposure to progressively increased concentrations of gemc-
tabine over a 12-month period as previously described [28]. Both
ines were grown at 37 ◦C in the presence of 5% CO2, in RPMI
640 containing l-glutamine and supplemented with 10% (v/v)
eat-inactivated fetal bovine serum,penicillin (100unitsmL−1) and
treptomycin (0.1mgmL−1). The medium was renewed every 3
ays..4. Stock and working standard solutions
Stock standard solutions of araCTP, BrATP and ClATP
500gmL−1) were prepared precisely by weighing out 0.5mg
f powder which was dissolved in 1mL of ultrapure water. Stockstandard solutions of CTP* and dCTP* (50gmL−1) were pre-
pared by diluting commercial solutions (1mM) in MilliQ water.
A series of working standard solutions of araCTP, CTP*, dCTP*
were prepared by subsequent dilution of the above-mentioned
stock standard solutions in MilliQ water to reach concentration
ranges of 0.5–50gmL−1 for araCTP, 0.05–50gmL−1 for CTP*
and 0.05–50gmL−1 for dCTP*. Working standard solutions of
the internal standards, BrATP and ClATP (50gmL−1) were also
prepared by subsequent dilution of the above-mentioned stock
standard in MilliQ water. Stock and working standard solutions
were stored at −80 ◦C.
2.5. Cell extract preparation
Cell extracts were prepared from the human follicular lym-
phoma cell line (5×106 cells/sample). Cell culture medium was
removed by centrifugation (290× g, 10min, 5 ◦C) and cells were
washed three times with cold phosphate-buffered saline (PBS, 3×
500L/5×106 cells). After centrifugation (290× g, 10min, 5 ◦C),
the cell pellet was resuspended in a solution containing 60%
methanol (250L/5×106 cells), vigorously vortex mixed for 15 s
and kept overnight at −20 ◦C to precipitate proteins. The follow-
ing day, cell debris were removed by centrifugation at 13,200× g
for 3min at room temperature, and the supernatant was extracted
using WAX SPE procedure or directly stored at −80 ◦C for samples
used to study matrix effect).
2.6. WAX SPE procedure
The cartridges were preconditioned by passage of 2mL of
methanol and 2mL of milliQ water. Supernatant obtained dur-
ing cell extract preparation was diluted with 1.75mL of solution
MeOH/H2O (60/40, v/v). This biological samplewas passed through
the preconditioned cartridges at a rate of 1 drop s−1. The cartridges
were then washed (2mL of 50mM ammonium acetate buffer,
pH 4.5) and the target analytes (NuTP) were eluted with 2mL of
MeOH/H2O/NH4OH (24/5/1, v/v/v). Finally, sample was evaporated
to dryness under a nitrogen stream at room temperature. Samples
were stored at −80 ◦C until LC/MS/MS analysis.
2.7. Validation procedure
Validation of the analytical method was performed accord-
ing to the FDA guidance [29]. The validation parameters included
speciﬁcity, linearity, intra- and inter-assay precision and accuracy,
extraction recovery and stability.
The speciﬁcity of the proposed method toward endogenous cell
extract compounds was tested in ﬁve different batches of drug-free
cell extract by analyzing blanks, samples containing no drug but
the internal standard and cell extract samples spiked with araCTP,
dCTP* and CTP* at their corresponding 3× LOQ levels and internal
standard at 4gmL−1 (Fig. 2A and B).
Three different calibration curves were performed in cell
extracts and analyzed on three separate days. Each calibration
curve consisted of one “blank” cell extract and seven calibration
standards. Calibration spiked cell extract standards were prepared
fresh daily by dilution of working standard solutions of unlabelled
araCTP and labelled compounds (CTP* and dCTP*) as well as the IS
(BrATP) with 250L of cell pellets (5×106 cells) obtained before
proteins precipitation step. Spiked cell extract calibration stan-
dards at seven different concentration levels 0.10, 0.30, 0.50, 1.00,
2.00, 4.00 and 8.00gmL−1 for araCTP, 0.01, 0.03, 0.10, 1.00, 2.00,
10.00 and 30gmL−1 for CTP*, 0.01, 0.03, 0.30, 0.50, 1.00, 4.00 and
8.00gmL−1 for dCTP* were prepared (Table 2). Each calibration
sample contained4gmL−1 of the internal standard. Then, all sam-
ples (calibration standard and QC) were loaded on phase extraction
s
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(upport (solid phase extraction (SPE)) Oasis® WAX cartridges and
nalyzed by LC/MS/MS. The calibration curves were drawn by plot-
ing the peak area ratio of each compound (araCTP, CTP*, dCTP*) to
he signal area of the internal standard (BrATP) versus the nominal
oncentration (gmL−1) of each analytes in cell extract.Six independent replicates (n=6) of the quality control (QC)
amples were also prepared at four concentration levels 0.1, 0.3,
and 8gmL−1 for araCTP, 0.01, 0.03, 10 and 30gmL−1 for CTP*
nd 0.01, 0.03, 4 and 8gmL−1 for dCTP* and tested the same day
n order to assess intra-day variability. All QC samples were freshly
ig. 2. Ion chromatograms of (A) blank cell extract, (B) cell extract spiked with araCTP (0
C) samples containing no drug but the internal standard.prepared for each run. Inter-assay performance was monitored in
four replicates at three levels during three different days.
2.7.1. Accuracy and precision
The accuracy was determined by comparing the means of theconcentrations found in the quality control samples with the theo-
retical values. Precision was represented as coefﬁcient of variation
(CV) in percentage (%CV). The acceptance criteria for within- and
between-batch precision were 20% or less of the coefﬁcient of
variation for lower limit of detection (LLOQ) and 15% or less
.3gmL−1), CTP* (0.03gmL−1), dCTP* (0.03gmL−1) and BrATP (4gmL−1) and
(Cont
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8Fig. 2.f the CV for the other concentrations, and for accuracy were
0–120% of the nominal value at the LLOQ and 85–115% of the
ominal value at the other concentrations. The lower limit of
etection (LLOD) was determined at a signal-to-noise (S/N) ratio
able 2
inearity of araCTP, CTP* and dCTP* in cell extract from RL-7 cells was determined by ana
f seven points in three replicates for each concentration. Data were represented as mean
urves ranges (gmL−1) araCTP
raCTP CTP* dCTP* CV (%) RE (%)a mean (n=3)
.1 0.01 0.01 8.9 0
.3 0.03 0.03 2.4 5.7
.5 0.1 0.3 8.5 0.4
1 0.5 0.3 −10.1
2 1 6.9 −1.1
10 4 4.1 −8.5
30 8 2.9 5.5
a [(Mean measured concentration− spiked concentration)/spiked concentration]×100inued)of 3. The lower limit of quantiﬁcation, the lowest concentration
in the calibration curve that can be determined with accept-
able accuracy and precision, was measured at a minimum S/N
ratio of 10. The between-run precision (BRP), and accuracy of
lysing three separate analytical batches. Each batch contained standards consisting
of three samples.
CTP* dCTP*
CV (%) RE (%)a mean (n=3) CV (%) RE (%)a mean (n=3)
6.7 0 5.7 0
7.5 6.7 7.6 13.3
6.1 8 2.4 7.7
3.7 −12 3.5 −12.8
8.9 −1.6 6.7 0.4
3.1 −9.5 5.6 −7.1
1.3 3.7 13.2 −5.1
.
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dig. 3. Chromatogram obtained at =272nm for a mixture of araCTP, CTP, araCDP, C
0mm×2.1mm (ThermoFisher). The mobile phase consisted of two eluents. Eluent
ith glacial acetic acid. Eluent B was acetonitrile/water (50/50, v/v). The ﬂow-rate w
he method were evaluated on three separate days by four repli-
ates analysis of quality control containing araCTP, dCTP* and CTP*
t concentration of 0.1, 4, 8ngmL−1, 0.01, 4, 8ngmL−1 and 0.01,
0, 30ngmL−1, respectively in cell extract from RL-7 cells. An
stimate of the BRP was obtained by one-way analysis of vari-
nce (ANOVA) for each test concentration using “run day” as
he classiﬁcation variable. The BRP was estimated as BRP = 100 ×√
(MSbet − MSwit)/n/GM). MSwit, MSbet, n, GM, represented the
ithin-groups mean square, the between-groups mean square, the
umber of replicate observations within each run and the grand
ean, respectively. These parameters were calculated using the
oftware Statview for Windows Version 5.0 (SAS Institute, Cary,
SA).
Stability experimentswereperformed toevaluate the stability of
ach analyte and IS in cell extract sample or in free cell extract sam-
le under different temperature and timing conditions and under
onditions used during the extraction procedure. Three aliquots of
C free cell extract of mid concentration were subjected to the
ollowing conditions: three freeze–thaw cycles (−80 ◦C to room
emperature), storage (3 weeks at −80 ◦C), storage at room temper-
ture for 1h under acidic conditions or 3h under basic conditions
sed for SPE WAX extraction.
The stability of QC prepared in cell extract of mid-concentration
as also assessed after addition ofMeOH/H2O (60/40, v/v) and kept
or 24h at −20 ◦C. Post-preparation stability was assessed by ana-
yzing the extracted QC samples kept either in the autosampler
t 4 ◦C for 24h or at room temperature for 7h that exceeded the
outine preparation time of samples.
able 3
ntra-assay performance data for araCTP, CTP* and dCTP* in cell extract from the human fol
ere analyzed in the same run (n=6).
ompound Nominal concentration (gmL−1) Measured concentra
raCTP 0.100 0.102 ± 0.007
0.300 0.315 ± 0.021
4.00 3.85 ± 0.34
8.00 7.80 ± 0.82
TP* 0.010 0.010 ± 0.001
0.030 0.031 ± 0.003
10.00 10.07 ± 0.91
30.00 28.89 ± 3.36
CTP* 0.010 0.010 ± 0.001
0.030 0.032 ± 0.003
4.00 4.16 ± 0.47
8.00 8.44 ± 0.63MP and araCMP in water. Separation was performed on a hypercarb column, 5m,
s water with hexylamine (HA, 5mM) and DEA (0.4%, v/v), the pH was adjusted to 10
3mLmin−1 and the temperature of the analytical column was maintained at 30 ◦C.
2.8. Extraction recoveries
Extraction recoveries were carried out at concentrations of 0.1,
4 and 8gmL−1 for araCTP, 0.01, 10, 30gmL−1 for CTP and 0.01,
4 and 8gmL−1 for dCTP, and 4gmL−1 for BrATP with ﬁve sam-
ples of each concentration. For the determination of the absolute
recovery of various analytes and the IS from the extraction proce-
dure, the method described by Matuszewski et al. [30] was applied.
The absolute recovery was determined by a comparison of the peak
areas derived from cell extract samples (QC samples at three con-
centrations,withﬁve samples for eachconcentration) spikedbefore
proteins precipitation step with the peak areas derived from cell
extract samples spiked after the extraction procedure with the
same amount of analyte. To determine the extraction recovery of
BrATPweusedClATP as IS. This ISwas used to determine the extrac-
tion recovery of other compounds.
2.9. Matrix effect
We studied the matrix effect on ionisation only for araCTP
because this compound was suspected to be present in cell extract
at a lower concentration and it was the compound of interest. The
matrix effect before and after SPE extractionwas evaluated by com-
paring the results of analysis of three sets of samples in according
to Matuszewski et al. [30]. In the ﬁrst set (A) two levels of stan-
dards, dissolved in HPLC mobile phase, were analyzed in triplicate
(six samples). In the second set (B), samples were spiked with two
levels of araCTP after proteins precipitation step. Samples were not
licular lymphoma cell line RL-7. Six separately spiked samples at each concentration
tion (gmL−1) mean± S.D. (n=6) Accuracy (%) Precision (%)
102.0 6.9
105.0 6.9
96.3 8.1
97.5 10.5
100 12.6
103.3 11.7
100.7 9.0
96.3 11.6
100.0 7.9
93.4 10.8
96.0 11.4
94.5 7.5
Table 4
Assessment of accuracy and precision in cell extract from RL-7 cells. Inter-assay was carried out at three concentrations on three different days with four replicates (n=12).
Concentration (gmL−1) Accuracy (%) Precision (%), between-run
Spiked Found (mean± S.D.)
araCTP
0.1 0.103 ± 0.008 103.1 4.7
4 4.16 ± 0.38 103.9 7.1
8 7.95 ± 0.90 99.3 4.1
CTP*
0.01 0.0102 ± 0.0012 102.0 1.6
10 10.24 ± 0.88 102.4 1.3
30 30.68 ± 2.89 102.5 7.6
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0.01 0.010 ± 0.001
4 4.22 ± 0.41
8 8.29 ± 0.72
ubjected to SPE extraction. In the third set (C), samples from cell
xtract were extracted using SPE and then spiked with two lev-
ls of araCTP. For sets, A–C, the peak area ratios were calculated
etween analyte and BrATP (IS). The matrix effect (ME) with or
ithout used SPE was calculated as follows: ME (%) =C/A×100 and
E (%) =B/A×100, respectively.
.10. Application: incubation of cells with araC or
is(SATE)araCMP prodrug
For each experiment, 5 million cells were incubated in presence
f araC (10M)or bis(SATE)araCMPprodrug (10M)at 37 ◦Cunder
5% CO2 atmosphere for 6h. After incubation, cells were harvested
y centrifugation (1200 rpm, 10min, 5 ◦C),washed three timeswith
00L of cold PBS then internal standard (BrATP) was added. The
etabolites present in the cell pellet were extracted by addition of
50L of solution MeOH/H2O (60/40, v/v). This solution was vig-
rously vortex mixed for 15 s and stored overnight at −20 ◦C. The
ay after, cell debris were removed by centrifugation at 13,000 rpm
or 3min at room temperature and the supernatant, which con-
ained the intracellular metabolites, was diluted with 1.75ml of a
ethanol/H2O (60/40, v/v) solution. Then, the sampleswere loaded
n phase extraction support (SPE) using a procedure previously
escribed.
. Results and discussion
.1. Method development
Because araCTPhas the samemolecularmass as CTP the endoge-
ous nucleotide, naturally present in cells and also the same major
aughter ion (m/z 159), chromatographic separation between these
wo compounds was required prior to MS detection and quan-
iﬁcation. During the last decade, porous graphitic carbon has
merged as a new packing material for polar analytes [31] includ-
ng nucleotides [32,33] and this material was used to resolve
tructurally related compounds. In addition, due to its chemical
able 5
ecovery percentages obtained for araCTP, dCTP*, CTP* and BrATP in cell extract from the
Concentration (gmL−1)
Low Middle
0.1 0.01 0.01 4 4
araCTP dCTP* CTP* BrATP ara
ield (%) 81.9 60 73.8 81 81
V (%) (n=5) 5.1 12.9 19.6 1.31 2.2100.7 2.5
105.6 7.9
103.6 6.7
nature and physical structure, the PGC stationary phase tolerates
a wide pH range (0–14). Therefore, we decided to test whether
the separation of araCTP and CTP could be performed using PGC
as the stationary phase. In preliminary PGC experiments, we have
shown that this stationary phase provides adequate selectivity for
the separation of araCMP from CMP [33]. However, the mobile
phase (0.1% formic acid with ACN) used in this experiment eluted
only nucleosides and nucleoside 5′-monophosphates while the
nucleoside 5′-triphosphates were trapped on the column. As previ-
ously demonstrated [32], even a high concentration of formic acid
(50mM)didnot elute nucleoside 5′-triphosphates, presumably due
to insufﬁcient competition with electronic interactions between
triphosphates and the PGC surface [34].
Due to the high polarity of the analytes and in order to improve
their separation, the addition of different ion-pairing agents in
the aqueous mobile phase was investigated. The ion-pairing agent
acts as a counter ion for the acidic nucleotides, thereby facilitat-
ing their elution from the column. Alkylamines were shown to
be promising ion-pairing agents for acidic analytes [35] and we
tested several alkylammonium salts. By using 20mM TEAAc in the
aqueous mobile phase, CTP and araCTP could not be separated.
The effect of TEAAc concentration on chromatographic behaviour
was checked in the 5–50mM range but no improvement in selec-
tivities was observed. As previously described by Coulier et al.
[36], hexylamine may be used as ion-pairing agent to analyse
nucleotides on a reversed phase column. Thus, we have shown that
the amount of hexylamine could be minimized to 5mM and led to
good retention of analytes and minimal contamination in the MS
source.
Under chromatographic conditions described above, we
observed a peak tailing probably due to strong interactions
between the PGC phase and the phosphate groups. To improve
the peak shape, the effect of diethylamine (DEA) as a modiﬁer
was evaluated at various concentrations. The ion pairing between
DEA and the phosphate group was expected to reduce interactions
between analytes and PGC, and thus may improve peak shape
[32]. With the addition of 0.4% DEA, reasonable peak shapes were
human follicular lymphoma cell line RL-7.
High
4 10 8 8 30
CTP dCTP* CTP* araCTP dCTP* CTP*
.9 73 84.6 75.2 72.5 63
4.4 7.7 2.6 2.4 15.9
Table 6
Matrix effect (ME).
Concentration araCTP
4gmL−1 8gmL−1
Standard solutions (A) Ratio (drug/IS) (mean± S.D.) (n=3) 2.87±0.19 6.17±0.23
Cell extract spiked after protein extraction and before SPE extraction (B) Ratio (drug/IS) (mean± S.D.) (n=3) 2.06±0.09 4.44±0.29
Cell extract spiked after protein extraction and with SPE extraction (C) Ratio (drug/IS) (mean± S.D.) (n=3) 3.01±0.09 6.21±0.14
ME % without SPE 71.8 72.0
ME % with SPE 106.0 100.6
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BA) Two concentration points of standards were dissolved in HPLC mobile phase
amples were not extracted by SPE. (C) Three cell extracts were extracted by SPE and
%) =B/A×100 and with SPE, ME (%) =C/A×100.
btained (Fig. 3). All these assays were initially performed by UV
etection.
It was essential to optimize the pH of the mobile phase in
rder to obtain signiﬁcant retention of the analytes, peak shapes
nd correct mass spectrometry response. A pH value of 10 for the
obile phase A was found to be the optimum for the nucleotides
etention. A pH of 7 was required for the mobile phase B, espe-
ially to allow the formation of ion-pair between hexylamine
nd nucleotides, thus reducing electronic interactions between
riphosphates and the PGC surface. As illustrated in Fig. 3, this
ethod allowed chromatographic separation between each cou-
le of nucleotides: araCMP/CMP, araCDP/CDP and araCTP/CTP. The
ptimal MS response was obtained with ESI in negative mode.
.2. Validation study
.2.1. Speciﬁcity
Blank matrix from ﬁve batches was tested for endogenous
nterference. Under optimized HPLC and MS conditions, blank cell
xtracts showed no signiﬁcant interfering peaks at the retention
imes of each analytes or the IS (Fig. 2).
.2.2. Linearity
For araCTP and CTP*, calibration curves were constructed using
linear regression (Y= aX+b) and a 1/X weighted regression was
sed. For dCTP*, the best ﬁt was obtained by using a quadratic
egression model with 1/X2 weighting.
The mean coefﬁcients of determination (r2) for the validation
uns were 0.9937 for araCTP, 0.9960 for CTP* and 0.9865 for dCTP*.
he calibration curves (Table 2) for both analytes were acceptable
ccording to the validation criteria as the back-calculated values
ere within ±15% of the nominal concentrations (±20% at the
LOQ) in the 3-day validation. The LLOD and the LLOQ in cell
xtracts were respectively 0.05 and 0.1gmL−1 for araCTP, 0.005
nd 0.01gmL−1 for both CTP* and dCTP*.
able 7
oncentrations of araCTP, CTP and dCTP (gmL−1) observed in parental RL-7 and resistant
f araCTP concentration in RL-7 and RL-G cell lines.
ompound incubated RL-7 cell line
[araCTP]a [CTP]a [dCTP]a
raC (10M) >8 8.37 0.53
CV=6.6% CV=13.4% CV=23.6%
ncubation prodrug of
raCMP (10M)
1.32 9.87 1.02
CV=5.9% CV=5.8% CV=7.8%
lank cell culture NDb 6.71 0.91
– CV=3.5% CV=1.7%
a Data was represented as mean of three separate experiments (n=3).
b Not detected.nalyse in triplicate. (B) Three cell extracts were spiked with two levels of araCTP,
d with two levels of araCTP. ME values were calculated as follows: without SPE, ME
3.2.3. Intra- and inter-day accuracy and precision
Tables 3 and 4 show the validation results for intra- and inter-
day assay accuracy and precision. For the QC samples, the intra-day
and inter-day accuracy of araCTP were from 96.3% to 105% and the
inter-day and intra-day precisionwas less than 10.5%. The inter-day
and intra-day accuracy of dCTP* were from 93.4% to 105.6% and the
inter-day and intra-day precision was less than 11.4% For CTP*, the
inter-day and intra-day accuracywere from96.3% to 103.3% and the
inter-day and intra-day precision was less than 12.6%. These results
satisﬁed the acceptance criteria and consequently the analytical
method was judged to be reproducible in terms of intra- and inter-
day accuracy and precision.
3.2.4. Stability
Stability during sample handling (repeated freeze–thaw and
ambient thaw) and for processed samples (extracts) was tested. All
analytes (araCTP, dCTP* and CTP*) and IS (BrATP and ClATP) demon-
strated to be stable through three freeze–thaw cycles (−80 ◦C to
room temperature), storage 3 weeks at −80 ◦C, storage at room
temperature for 1h under acidic conditions and 3h under basic
conditions (used for SPE WAX extraction).
The stability of QC in cell extracts prepared prior to extraction
andkept for 24hat−20 ◦Cwasalso assessed. The samples remained
stable.
Post-preparation stability was assessed by analyzing the
extracted QC samples kept either in the autosampler at 4 ◦C for 24h
or at room temperature for 7h, duration that exceeded the routine
preparation time of samples.
In all conditions tested, QC samples remained stable.
3.2.5. Recovery and matrix effect
Absolute recoveries were determined by comparing the peak
areas of extracted QC samples with the peak areas of matrix recov-
ery samples prepared by adding compound to post-extraction
matrix blanks at the corresponding QC concentrations. The mean
recoveries were at least 75.2%, 60%, 63% and 81% for araCTP, dCTP*
RL-G cell lines after 6h of exposure to 10M of araC or of prodrug of araCMP. Ratio
RL-G cell line [araCTP]RL/[araCTP]RL-G
[araCTP]a [CTP]a [dCTP]a
<0.1 7.99 0.06 >177
CV=12% CV=21.0% CV=12.9%
0.18 10.04 0.10 7
CV=10.9% CV=10.6% CV=16%
ND 9.52 0.09 –
– CV=6.4% CV=6.1%
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[TP* and BrATP, respectively, for all three QC concentrations from
ell extracts (Table 5). The effects of ion suppression on the peaks
efore and after SPE extraction were compared (Table 6). These
esults indicated that SPE extraction allow to reduce matrix effects.
.3. Incubation studies: application
To circumvent cellular resistance due to a reduced intracellular
oncentration of araCMP, prodrugs of araCMP (compound 1, Fig. 1)
ave been developed. These compounds are expected to enter
ells by passive diffusion and then to convert into araCMP, thus
vercoming reduced nucleoside transport and/or deoxycytidine
inase deﬁciency. We have previously demonstrated that mononu-
leoside phosphotriester derivatives bearing two SATE moieties as
ransient phosphate protecting groups were able to deliver the cor-
esponding 5′-mononucleotide inside the cell through an esterase
ediated activation process [37]. Using a dCK-expressing and deﬁ-
ient lymphoma cell model, we compared the ability of compound
, comparatively to araC, to allow the intracellular delivery of
raCMP and thus circumvent araC resistance caused by dCK deﬁ-
iency and/or lack of nucleoside transport.
Human follicular lymphoma cell lines RL-7 and RL-G were incu-
ated for 6h with araC or the bis(SATE) araCMP prodrug at 10M.
oncentrations of araCTP, CTP and dCTP determined by LC–MS–MS
re reported in Table 7. Incubation of araC in RL-7 cells resulted
n the accumulation of araCTP. In contrast, a very small amount
f araCTP was detected in RL-G cells. Since the ﬁrst phosphory-
ation step of araC is catalyzed by deoxycytidine kinase, this data
as consistent with the lack of dCK activity in RL-G cell line. Con-
ersely araCTP was formed upon incubation of either RL-7 or RL-G
ells with the araCMP prodrug. However, araCTP concentrationwas
ound at an 7-fold lower concentration in RL-G cells than in RL-7
ells. This lower accumulation of araCTP in RL-G cells is presumably
ue toother cellularmechanisms involved inaraC resistance suchas
ncreased level of 5′-nucleotidase or deﬁciency in nucleoside trans-
ort [38]. The ratio of [araCTP]RL/[araCTP]RL-G was 25-fold higher in
raC-treated cells than in araCMP prodrug-treated cells (Table 7).
hus, demonstrating that the pronucleotide of araCMP was able to
eliver araCTP inside cells and to overcome deoxycytidine kinase-
ediated resistance.Our results are thus consistentwithpreviously
ublished data [39]. As shown in Table 7, the intrinsic dCTP levels
n RL-G cell line were 10-fold lower than in the parental RL cell line,
hile the CTP levels of the resistant cell lineswere not affected. This
iscrepancy in dCTP pools has been already observed in AG6000
ells line having dCK deﬁciency [40].
. Conclusions
We have developed and validated a new LC/MS/MS method to
uantify araCTP, CTP and dCTP in human cell extracts. As the levels
f endogenous compounds (CTP and dCTP) may vary according to
ell extracts, stable isotope labelled nucleotides (CTP* and dCTP*)
ere used to build standard curves and for needs of validation.
ample preparation was performed by solid phase extraction. Sep-
ration of nucleotides was achieved on a PGC stationary phase and
his material has a great potential for nucleotides analysis. Hexy-
amine and DEA have proved to be excellent ion-pairing reagents
or CTP and araCTP separation. Finally, thismethodwas successfully
pplied to apharmacokinetic study in ahuman follicular lymphoma
ell line. The ratio of [araCTP]/[dCTP] and [araCTP]/[CTP]weremon-
tored after the incubation of cells with araC and of a bis(SATE)
rodrug of araCMP.
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